36 results on '"Cirilli, N."'
Search Results
2. P477 How the use of nocturnal non-invasive ventilation and oxygen therapy changes in patients with cystic fibrosis using elexacaftor/tezacaftor/ivacaftor
3. P348 Nutritional challenges in the era of cystic fibrosis transmembrane regulator modulators: can we still trust the body mass index?
4. P017 Sweat test: different clinical questions require different lab reports
5. P413 How to use telemonitoring for the detection of respiratory exacerbations in cystic fibrosis: effectiveness and adherence
6. P040 Sweat chloride values in cystic fibrosis patients after one year on elexacaftor/tezacaftor/ivacaftor
7. P129 Evidence for a role of Achromobacter xylosoxidans VBNC forms in chronic cystic fibrosis lung infection
8. P162 Body composition assessment in cystic fibrosis (CF) patients on elexacaftor/texacaftor/ivacaftor
9. P207 Spirometric values and 6-minute walking distance in cystic fibrosis patients on elexacaftor/texacaftor/ivacaftor
10. P113 Microbiology assessment in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor
11. P032 Sweat chloride values in cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor
12. Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme
13. Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme
14. P020 CFTR mutation panel in detecting cystic fibrosis screen positive inconclusive diagnosis patients (CFSPIDs) in the Marche Region, Italy
15. P007 A novel cystic fibrosis-causing mutation identified in a newborn of African origin
16. P029 Validation of new sweat test control materials
17. P005 Lessons from 5T;TG12
18. P278 Cataloguing outcome measures of cystic fibrosis clinical studies
19. Real life practice of sweat testing in Europe
20. 111 Non-tuberculous mycobacteria in patients with cystic fibrosis: detection and isolation from respiratory samples. Results of a cross-sectional study
21. WS10.6 Intra-individual biological variation in sweat chloride concentrations
22. 428 Are cystic fibrosis guidelines credible? Evaluating methodological issues
23. WS11.4 Real life practice of sweat testing in Europe: results from an ECFS-wide survey
24. 62 Molecular diagnosis of Pseudomonas aeruginosa infection in culture-negative samples from cystic fibrosis patients
25. 282 Patient priorities for research in cystic fibrosis: the IPaCOR experience
26. 26 Risk factors for poor outcomes in cystic fibrosis newborns diagnosed by neonatal screening in Italy: years 2009–2011
27. 281 Patient-centered outcomes in CF research
28. 10 The role of complex alleles in patients with cystic fibrosis and L997F
29. WS21.3 Clinical variability in patients with cystic fibrosis and D1152H mutation
30. A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis
31. 20 Cystic fibrosis newborn screening in Italy: survey for assessment of technical-scientific and organizational issues
32. 290 Oral DHA supplementation in children with cystic fibrosis: a randomized placebo-controlled study
33. EMERGENCE OF COLISTIN-RESISTANT PSEUDOMONAS AERUGINOSA FROM ITALIAN CYSTIC FIBROSIS PATIENTS
34. Pseudomonas aeruginosa (PA) resistant to colistin (CL) in Italian cystic fibrosis (CF) patients
35. 110 Genetic fingerprinting of Pseudomonas aeruginosa (PA) from Italian CF patients (pts): comparison with isolates from environment and other clinical origins in Europe
36. 73* Occurrence of P. aeruginosa (PA) with hypermutable phenotype (HPM) in Italian CF patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.